Drug Delivery and Translational Research ( IF 5.7 ) Pub Date : 2022-06-13 , DOI: 10.1007/s13346-022-01194-7 K Laxmi Swetha 1 , Kavya Sree Maravajjala 1 , Shyh-Dar Li 2 , Manu Smriti Singh 3, 4 , Aniruddha Roy 1
|
Most of the current antitumor therapeutics were developed targeting the cancer cells only. Unfortunately, in the majority of tumors, this single-dimensional therapy is found to be ineffective. Advanced research has shown that cancer is a multicellular disorder. The tumor microenvironment (TME), which is made by a complex network of the bulk tumor cells and other supporting cells, plays a crucial role in tumor progression. Understanding the importance of the TME in tumor growth, different treatment modalities have been developed targeting these supporting cells. Recent clinical results suggest that simultaneously targeting multiple components of the tumor ecosystem with drug combinations can be highly effective. This type of “multidimensional” therapy has a high potential for cancer treatment. However, tumor-specific delivery of such multi-drug combinations remains a challenge. Nanomedicine could be utilized for the tumor-targeted delivery of such multidimensional therapeutics. In this review, we first give a brief overview of the major components of TME. We then highlight the latest developments in nanoparticle-based combination therapies, where one drug targets cancer cells and other drug targets tumor-supporting components in the TME for a synergistic effect. We include the latest preclinical and clinical studies and discuss innovative nanoparticle-mediated targeting strategies.
Graphical abstract
中文翻译：
打破利基：用于肿瘤微环境调节的多维纳米疗法
大多数当前的抗肿瘤疗法都是针对癌细胞开发的。不幸的是，在大多数肿瘤中，这种单维疗法被发现是无效的。高级研究表明，癌症是一种多细胞疾病。肿瘤微环境 (TME) 由大量肿瘤细胞和其他支持细胞组成的复杂网络构成，在肿瘤进展中起着至关重要的作用。了解 TME 在肿瘤生长中的重要性，针对这些支持细胞开发了不同的治疗方式。最近的临床结果表明，使用药物组合同时靶向肿瘤生态系统的多个成分可能非常有效。这种“多维”疗法在癌症治疗方面具有很高的潜力。然而，这种多药组合的肿瘤特异性递送仍然是一个挑战。纳米医学可用于这种多维疗法的肿瘤靶向递送。在这篇综述中，我们首先简要概述了 TME 的主要组成部分。然后，我们重点介绍了基于纳米颗粒的联合疗法的最新进展，其中一种药物靶向癌细胞，其他药物靶向 TME 中的肿瘤支持成分，以产生协同效应。我们包括最新的临床前和临床研究，并讨论创新的纳米粒子介导的靶向策略。然后，我们重点介绍了基于纳米颗粒的联合疗法的最新进展，其中一种药物靶向癌细胞，其他药物靶向 TME 中的肿瘤支持成分，以产生协同效应。我们包括最新的临床前和临床研究，并讨论创新的纳米粒子介导的靶向策略。然后，我们重点介绍了基于纳米颗粒的联合疗法的最新进展，其中一种药物靶向癌细胞，其他药物靶向 TME 中的肿瘤支持成分，以产生协同效应。我们包括最新的临床前和临床研究，并讨论创新的纳米粒子介导的靶向策略。
京公网安备 11010802027423号